3 stocks crushed by the market this week   06-20-14
Upcoming SlideShare
Loading in...5
×
 

3 stocks crushed by the market this week 06-20-14

on

  • 5,048 views

3 of the worst health-care stocks of the week

3 of the worst health-care stocks of the week

Statistics

Views

Total Views
5,048
Slideshare-icon Views on SlideShare
270
Embed Views
4,778

Actions

Likes
0
Downloads
0
Comments
0

12 Embeds 4,778

http://www.fool.com 4704
http://m.fool.com 29
http://barchartjson.websol.barchart.com 15
http://translate.googleusercontent.com 6
http://www.barchart.com 6
https://translate.googleusercontent.com 5
http://www.seattlepi.com 5
https://cms.fool.com 4
http://www.greenwichtime.com 1
http://www.google.com 1
http://www.mysanantonio.com 1
http://www.slideee.com 1
More...

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx <br />
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx

3 stocks crushed by the market this week   06-20-14 3 stocks crushed by the market this week 06-20-14 Presentation Transcript

  • 3 Stocks Crushed by the Market This Week
  • They say that a rising tide lifts all boats. Despite a rising overall market, that old saying doesn’t hold water for these three health-care stocks.
  • Shares of the company specializing in plasma-based biopharmaceutical products dropped 10% for the week. China Biologic Products (NASDAQ:CBPO) Source: Yahoo! Finance
  • • China Biologic announced on Tuesday that it planned to sell another 1 million shares with some shareholders selling another 2.2 million shares in the secondary offering • Share dilution nearly always causes a stock to drop • In this case, the decline isn’t too bad for the amount of dilution of shares Why China Biologic shares hit a great wall
  • Shares of the biotech sank nearly 11% this week. TG Therapeutics (NASDAQ:TGTX) Source: Yahoo! Finance
  • • TG Therapeutics’ decline appears to be simply a case of profit-taking • On June 13, the company announced positive preliminary results from a phase 2 study of its TG-1101 in combination with Pharmacyclics’ (NASDAQ:PCYC) Imbruvica, resulting in a nice run-up in TG’s stock • Imbruvica is already approved as a second- line treatment for Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) • The two drugs combined achieved 90% overall response rate with 10 evaluable patients in the study Why TG Therapeutics shares tanked
  • The stock of this biotech fell almost 12% this week. Vertex Pharmaceuticals (NASDAQ:VRTX) Source: Yahoo! Finance
  • • Concerns expressed by analyst Geoffrey Porges with Bernstein weighed heavily on Vertex shares • Porges commented in a report that he thinks there is a high risk of failure with Vertex’s phase 3 study of cystic fibrosis drug VX809 • Two concerns about the VX809 trial stand out to Porges: – Some patients’ symptoms get worse before they get better – Positive effects might not be strong enough to justify the cost of the drug Why Vertex’s momentum vanished
  • • Vertex’s entire fate doesn’t rest on success with VX-809, but worries about the study could have some merit • China Biologic Products boasts solid earnings growth and should rebound from the latest public stock offering • The nod for best bet to mount a comeback, however, goes to TG Therapeutics • A pullback for TG was due with shares nearly doubling over the last month, but the future looks bright for the biotech Best shot at bouncing back?
  • Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!